Loading...

ATRA ATARA BIOTHERAPEUTICS INC Legal Disputes 8-K Filing

TR B

TR

ATARA BIOTHERAPEUTICS INC

(ATRA)

2026 8-K

Financial Results

Regulatory Update

Regulatory Update

Payment Amendment

Regulatory Update

Payment Amendment

Financial Results Report

Workforce Reduction

Board Restructuring

Financial Statements

Equity Offerings

Rights Offerings

Management Changes

Clinical Trials

Agreement Amendment

Management Changes

Financial Results

Workforce Reduction

Workforce Reduction

FDA Clinical Hold

Financial Update

Bylaw Amendments

Management Change

Management Change

Board Appointment

Leadership Changes

FDA Acceptance and Priority...

Reverse Stock Split

Reverse Stock Split

Annual Meeting of Stockholders

Financial Results

Departure of Directors

Financial Results Announcement

Departure of Directors or C...

Securities Purchase Agreeme...

Workforce Reduction

Announcement of Phase 2 EMB...

Sales Agreement with Cowen ...

Commercialization Agreement...

FDA Agreement on Comparability

Financial Results

Departure of Directors

Resignation and Voting Results

Resignation of EVP

Results of Operations and F...

Resignation of CFO

Disclosure of Cash Deposits

Financial Results and CFO R...

Transaction with HCR Molag ...

External Links:

On January 12, 2026, Atara Biotherapeutics announced the U.S. FDA issued a Complete Response Letter for their EBVALLO™ (tabelecleucel) Biologics License Application, indicating regulatory challenges ahead. This event is considered significant for the company, reflecting a negative sentiment regarding their product application.

AI Assistant

ATARA BIOTHERAPEUTICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.